Should I Buy GKOS? GKOS 2026 Analysis

Should You Buy Glaukos Corp (GKOS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

112.520

1 Day change

-0.88%

52 Week Range

161.780

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is breaking down into support with bearish momentum (negative/expanding MACD histogram).
Near-term sentiment is mixed-to-bearish (very high put/call volume ratio), which often pressures the stock in the immediate window.
Medium-term story remains attractive (FDA repeat-dosing label for iDose + strongly bullish Street posture), so this is a hold rather than a sell.
With earnings (QDEC 2025) on 2026-02-17 (after hours), near-term positioning risk is elevated for an impatient buyer.

Technical Analysis

Trend/MAs: Moving averages are still structurally bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader uptrend isn’t fully broken.
Momentum: MACD histogram -0.891 and negatively expanding = downside momentum currently strengthening.
RSI: RSI_6 37.36 = leaning weak (not oversold), leaving room for further drift lower.
Key levels: Post-market ~112.38 is sitting on/near S1 112.915 (important support). If lost, next support is S2 108.31. Upside resistance begins at pivot 120.367 then 127.82.
Pattern-based odds: Similar-pattern model implies modest expected moves (next week +1.36%), but that’s not strong enough to outweigh current momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (OI): Put/Call OI ratio 0.55 = more call open interest than puts (generally constructive).
Flow (Volume): Put/Call volume ratio 9.67 = today’s flow skewed heavily to puts (near-term bearish/hedging signal).
Volatility: 30D IV 64.33 vs HV 47.99 with IV percentile 77.69 = options pricing implies elevated uncertainty.
Volume context: Today’s options volume is low (32 contracts) but vs 30D avg it’s flagged as elevated; still, the extreme put/call volume ratio is a near-term caution flag.

Technical Summary

Sell

Buy

Positive Catalysts

- FDA approval allowing repeat administration of iDose TR labeling expands addressable use and supports an annuity-like model (multiple analysts explicitly cite this).
- Hedge funds: “Hedge Funds are Buying” with buying amount up 318.02% QoQ.
- Street narrative: multiple firms highlight 2026 setup with potential acceleration into 2027 (iDose + Epioxa ramp expectations).
- Stock context: After a weak 2025, January strength and FDA news can keep incremental buyers engaged on pullbacks.

Neutral/Negative Catalysts

- Insider activity: “Insiders are Selling” with selling up 1898.23% last month; recent notable sale by Director Marc Stapley (even though under a pre-scheduled plan).
- Technical momentum is currently bearish (MACD falling), and price is testing key support.
- Options tape shows heavy put-skewed volume today (near-term bearish sentiment/hedging).
- Event risk: Earnings on 2026-02-17 can drive gap risk; elevated IV reflects that uncertainty.
- No recent supportive signal from Intellectia proprietary modules today (no AI Stock Picker / no SwingMax).

Financial Performance

Latest provided quarter: 2025/Q3.
Revenue: $133.537M, up 38.14% YoY (strong top-line growth).
Profitability: Net income -$16.231M (more negative YoY by -24.19%), EPS -0.28 (down -28.21% YoY) = growth is not yet translating into earnings.
Margin: Gross margin 78.41%, up 2.31% YoY = underlying product economics improving despite losses.
Overall: strong revenue momentum + improving gross margin, but still loss-making (market will stay sensitive to forward guidance and commercialization pace).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets have been moving up with multiple price target raises (Citi 125, Needham 125, Truist 145, UBS 145, Stephens 145, Goldman 138, BTIG 131, Wells Fargo 122) and Stifel notably raised to $160.
Latest coverage: William Blair initiated at Outperform (no PT), calling for a solid 2026 and potential acceleration in 2027.
Wall Street pros: FDA repeat-dosing label expands iDose opportunity; reimbursement/utilization tailwinds; Epioxa survey work suggests potential revenue acceleration into 2027/2028.
Wall Street cons: Near-term financial challenges persist (losses), and execution/commercial ramp timing is key.
Politicians / Congress: No recent congress trading data available; no politician/influential-figure activity provided beyond the noted insider sale.

13 Analyst Rating

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72 USD and a high forecast of 165 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

1 Sell

Strong Buy

Current: 113.520

Low

Averages

127.08

High

165

Current: 113.520

Low

Averages

127.08

High

165

William Blair

Outperform

initiated

AI Analysis

2026-01-30

Reason

William Blair

Price Target

AI Analysis

2026-01-30

initiated

Outperform

Reason

William Blair assumed coverage of Glaukos with an Outperform rating and no price target. The firm sees a "solid" 2026 for the company, with pieces being put in place for significant sales acceleration in 2027. Glaukos is well positioned to "deliver best-in-class growth," the analyst tells investors in a research note.

Wells Fargo

Overweight

maintain

$122

2026-01-28

Reason

Wells Fargo

Price Target

$122

2026-01-28

maintain

Overweight

Reason

Wells Fargo notes that Glaukos has announced FDA approval of its repeat dosing label for iDose, in line with the firm's expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GKOS

Unlock Now

GKOS Should I Buy

GKOS Should I Buy

Should You Buy Glaukos Corp (GKOS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch